logo-loader
Immuron Ltd

Immuron’s shares surge on demonstrating proof of concept for liver drug candidate

Phase II clinical study results have revealed excellent safety and tolerability.

a representation of the human liver
Wider scope across a broad range of diseases

Immuron Limited’s (ASX:IMC) (NASDAQ:IMRN) IMM-124E has demonstrated a statistically significant reduction in serum lipopolysaccharide (LPS) levels, a major factor in liver inflammation.

The company’s shares were last trading circa 54% higher intra-day, at $0.44.

A total of 133 non-alcoholic steatohepatitis (NASH) patients were enrolled into Immuron’s phase II NASH clinical study and were treated with either IMM-124E or placebo for 6 months.

Results demonstrate a statistically significant reduction of serum LPS levels

64.29% of patients treated with IMM-124E demonstrated a 15% or greater decrease in serum LPS levels compared with only 34.48% of patients showing a decrease for the placebo group, reaching statistical significance.

Importantly, no safety concerns or serious adverse events were associated with the study drug.

The 600mg and 1200mg doses were well tolerated and support the use of even higher doses and extended treatment periods in future clinical trials.

Wider scope across a broad range of diseases

Immuron’s study results offer evidence of a therapeutic mechanism of action and a clear direction for further NASH studies.

The growing literature implicating LPS in many diseases offers the potential for a much wider scope for LPS antagonism as a treatment modality.

With IMM-124E being the world’s first-in class oral LPS antagonist, the company has substantial opportunities across a broad range of diseases.

READ: Immuron achieves strong sales growth for travellers’ diarrhoea product

The company’s flag-ship product Travelan® achieved a revenue in excess of $914,000 for the first six months of FY2018, experiencing strong sales growth in both the U.S. and Australia.

Travelan is a natural product, specifically designed to reduce the risk of infection by E.coli, the most common cause of travellers’ diarrhoea or Bali Belly.

Quick facts: Immuron Ltd

Price: $0.11

Market: ASX
Market Cap: $19.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Blackstone Minerals PGE assays a game-changer at Vietnamese...

Blackstone Minerals Ltd (ASX:BSX) managing director Scott Williamson updates Proactive on its maiden drilling program at the Ta Khoa Nickel Project in northern Vietnam, which has delivered the project's first-ever PGE assays. Assay results from the first of three drill holes at Ta Khoa have...

1 hour, 50 minutes ago

2 min read